Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Asia wins 2017’s mid-cap race
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Back to the future for small caps, but not all benefit
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
